Sign Up
Stories
BioSig Announces Reverse Stock Split
Share
Pulse Biosciences Expands Cardiac Ablati...
Revolutionizing Arrhythmia Care with $16...
Rudolf Riester GmbH Introduces Telemedic...
AI-Powered Raspberry Pi Stethoscope Inno...
Attune Medical's Growth in Esophageal Te...
BiVACOR Welcomes New CEO and FDA Approva...
Overview
API
BioSig Technologies, Inc. announces a reverse stock split of its common stock, aiming to improve cardiac ablation procedures with its non-invasive PURE EP™ Platform.
Ask a question
How might the reverse stock split impact BioSig's stock value and investor perception?
In what ways could BioSig's focus on deciphering heart rhythms contribute to advancements in medical technology?
What potential advantages does the non-invasive PURE EP™ Platform offer for cardiac ablation procedures?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage